Are you seeking to enhance your familiarity with most recent molecular NGS approaches that are crucial for fast and effective biomarker identification in solid tumours?
Discover how it is now possible to do next-generation sequencing (NGS) in as little as 24 hours with the speed and simplicity of immunohistochemistry.
Don't miss out on this outstanding chance to expand your horizons, and connect with our European network of pathologists.
Join us at ECP 2024 and pave the way for a brighter future in precision medicine.
Join our lunch symposium
Sunday, 8 September 2024: 13:00 - 14:30 CEST – Room Spadolini 6
> Add Reminder to Your Calendar
During our sponsored symposium you’ll discover more on:
Gain insights into the distribution of access to high-quality biomarkers through next-generation sequencing (NGS) testing across Europe and understand the implications of the latest ESMO (European Society for Medical Oncology) recommendations on your daily practice.
Unlocking blood cancer insight with NGS simplifying your path to answers in the study of lymphoid cancer.
How comprehensive genomic profiling (CGP) and homologous recombination deficiency (HRD) evaluation is enhancing precision medicine and advancing our understanding of ovarian cancer biology.
Dr. Nicola Normanno
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Italy
Dr. Geetha Menon
Royal Liverpool and Broadgreen University Hospital NHS Trust, UK
Prof. Dr. Wolfram Jochum
Kantonsspital St.Gallen, Institut für Pathologie, Switzerland
*For In Vitro Diagnostic Use. CE-IVD according to IVDD. Not available in all countries including the United States.
**For Research Use Only. Not for use in diagnostic procedures.
We've detected your location to be Japan.
Sorry, you cannot access this website. The content on www.oncomine.com is only intended for healthcare professionals. Formore information on our research solutions, please visit ThermoFisher.com
このウェブサイトは、日本国内の医療関係者の方への情報提供を目的としており、一般の方に対する情報提供を目的としたものではないことをご了承ください。研究用製品の情報はThermoFisher.comよりご覧ください。